A new era of information-based medicine
Precision medicine is a new step in healthcare
Méryl Roudaut* will present a poster on the work of Institut du Thorax
As shown by AstraZeneca in nature reviews, one third of the safety failures is linked to CNS toxicity during the clinical trials of drugs .
Quantifying DNA damage is mandatory to assess potential adverse effects of candidate drugs or molecules or extracts developed in the dermo-cosmetic industry, but also to assess the efficacy of therapeutic approaches with the aim of producing tumor cell genotoxicity in cancer treatment.
Since few years, the technology is more and more used to finaly create organ-on-a-chip and now body-on-chip with different organs.
« Phenotypic Drug Discovery with High Content Screening » by Permin Elmer
We will be present in the “innovation zone” during the Drug discovery 2015 in Telford the 2nd and 3rd of September in Telford.
Download our poster
NIH Grant has been awarded to Hudson Robotics and Johns Hopkins University for in vivo Studies. Cell imaging on in vivo studies on whole organism as zebrafish is a powerfull tool during drug discovery. Nevertheless, the throughput is really low to be used during preliminary drug discovery. Working on implementation Read more…
I was really impressed by the size and quality of the Drug Discovery 2014 organised by ELRIG in Manchester. More than 1,500 scientists participated in this meeting and nearly 100 exhibitors were present. Phentoypic screening and high content screening were prominent in this conference and we could hear researchers from Roche, Astrazeneca, Read more…